![](https://ml.globenewswire.com/media/e1bb572c-e8e6-4d59-95f7-14b89bd4d23f/small/new-logo-jpg.jpg)
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in …